Lexicon Pharmaceuticals’ (LXRX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report sent to investors on Monday morning,Benzinga reports.

Other analysts have also issued research reports about the company. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Stock Down 8.4 %

Shares of NASDAQ:LXRX opened at $0.76 on Monday. The business’s 50 day moving average is $1.14 and its 200 day moving average is $1.55. The stock has a market cap of $186.60 million, a P/E ratio of -1.01 and a beta of 1.07. Lexicon Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $3.73. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $1.75 million during the quarter, compared to analysts’ expectations of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same quarter in the prior year, the company posted ($0.21) earnings per share. Sell-side analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Compagnie Lombard Odier SCmA boosted its stake in Lexicon Pharmaceuticals by 6.4% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 100,000 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 6,000 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 13,246 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 13,972 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Lexicon Pharmaceuticals by 40.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 14,411 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.